Merck & Co
MRK
143.63
-2.32
-1.59%
Merck & Co
US · MRK
#43 by market cap
Listed 1970
143.63
-2.32
-1.59%
Live - 5344 symbols - heartbeat 29s ago
· 2026-10-20 08:29
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 81.53% +0.00pp
- Institutions
- 4,346 -10
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund68.39%
Public Company4.80%
Private Company2.38%
Government Pension Fund2.09%
Sovereign Wealth Fund1.59%
Hedge Fund1.06%
Family Office/Trust0.45%
Insurance Company0.28%
Corporate Pension Plan0.19%
Other18.77%
Top holders as of 2026-06-30
BlackRock
9.20% · 227.00M sh
Vanguard Capital Management, LLC
7.10% · 175.19M sh
State Street Global Advisors
4.88% · 120.41M sh
Wellington Management Group
3.50% · 86.25M sh
Vanguard Portfolio Management, LLC
2.75% · 67.74M sh
Other
72.58%
Geode Capital Management, LLC
2.46% · 60.74M sh
Charles Schwab Investment Management
2.20% · 54.37M sh
Fisher Investments
1.56% · 38.52M sh
Norges Bank Investment Management
1.50% · 36.98M sh
UBS Asset Management
1.35% · 33.29M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 41 buys · 8 sells
| Name | Role | Stake |
|---|---|---|
| Robert Davis | Chairperson & CEO | 0.02% |
| Sanat Chattopadhyay | Executive VP & President of Merck Manufacturing Division | 0.01% |
| Richard DeLuca | Executive VP & President of Merck Animal Health | 0.00% |
| Dean Li | Executive VP & President of Merck Research Laboratories | 0.00% |
| Caroline Litchfield | Chief Financial Officer | 0.00% |
| Jennifer Zachary | Executive Vice President | 0.00% |
| Chirfi Guindo | Senior VP & Chief Marketing Officer for Merck Human Health | 0.00% |
| David Williams | Executive VP and Chief Information & Digital Officer | 0.00% |
| Joseph Romanelli | Senior VP & President of Human Health International | 0.00% |
| David Maraldo | Executive VP & President of Merck Manufacturing Division | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Christine Seidman | Independent Director | Other Derivative Acquisition | +55 | -- |
| 2026-09-29 | Surendralal Karsanbhai | Independent Director | Other Derivative Acquisition | +111 | -- |
| 2026-09-29 | Mary Coe | Independent Director | Other Derivative Acquisition | +206 | -- |
| 2026-08-31 | Gaurav Gupta | Executive Vice President and Chief Information & Digital Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-12 | Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications | Open Market Disposition | -10,000 | $135.00 |
| 2026-08-11 | Richard DeLuca | Executive VP & President of Merck Animal Health | Open Market Disposition | -45,320 | $130.43–132.35 |
| 2026-08-11 | Jennifer Zachary | Executive Vice President | Open Market Disposition | -25,388 | $133.46 |
| 2026-08-11 | Jennifer Zachary | Executive Vice President | Derivative Exercise and Sale | -54,927 | $84.71–133.46 |
| 2026-08-05 | Richard DeLuca | Executive VP & President of Merck Animal Health | Open Market Disposition | -6,050 | $130.23–131.02 |
| 2026-08-05 | Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications | Open Market Disposition | -15,000 | $131.00 |
| 2026-08-04 | David Williams | Former Executive VP and Chief Information & Digital Officer | Derivative Exercise and Sale | -52,847 | $73.73–128.77 |
| 2026-08-04 | David Maraldo | Executive VP & President of Merck Manufacturing Division | Derivative Exercise and Sale | -18,706 | $73.73–128.72 |
| 2026-06-29 | Christine Seidman | Independent Director | Other Derivative Acquisition | +63 | -- |
| 2026-06-29 | Surendralal Karsanbhai | Independent Director | Other Derivative Acquisition | +126 | -- |
| 2026-06-29 | Mary Coe | Independent Director | Other Derivative Acquisition | +233 | -- |
| 2026-05-28 | Pamela Craig | Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Patricia Russo | Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Thomas Glocer | Lead Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Risa Lavizzo-Mourey | Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Douglas Baker | Independent Director | Other Derivative Acquisition | +1,853 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 08:29:32 · For reference only, not investment advice and not tailored to your situation.
the keytruda patent cliff is a few years out but the market’s already discounting it hard. pipeline needs to deliver or this stays cheap for a while, that’s the whole debate in one sentence.